Pharmafile Logo
Pharmafocus logo
Advanced Search

madrigal

Showing 1 posts of 1 posts found.

clinical_trial_4

Synta Pharmaceuticals announces merger with Madrigal

April 15, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger

Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026